Alex Biese

Patients with mCRPC who received Ra-223 were not found to be at a higher relative risk of hematological toxicity if they had received prior EBRT.

Patients with unresectable hepatocellular carcinoma treated with regorafenib experienced more frequent serious TEAEs if they had Child-Pugh B liver function.

Patient care begins with the patient, and Deb Schrag, MD, MPH, has spent her career keeping them the main focus of improving oncologic outcomes.

The addition of isatuximab-irfc to carfilzomib, lenalidomide, and dexamethasone was well tolerated and elicited a 100% objective response rate in standard- and high-risk, transplant-eligible patients with newly diagnosed multiple myeloma.

Zanidatamab in combination with palbociclib and fulvestrant resulted in positive progression-free survival outcomes and exhibited an acceptable safety profile in patients with hormone receptor–positive, HER2-positive metastatic breast cancer.

Treatment with fixed-duration venetoclax plus rituximab continued to show superior survival benefit vs bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia, according to 7-year follow up data from the phase 3 MURANO trial.

Positive changes in symptoms of anxiety and depression were reported in patients with cancer following the use of a cognitive behavioral stress management app.